ATLANTA, Nov. 11 /PRNewswire-FirstCall/ -- CryoLife, Inc. (NYSE: CRY), an
implantable biological medical device and cardiovascular tissue processing
company, announced today that Steven G. Anderson, president and chief
executive officer of CryoLife, Inc., is scheduled to present in the upcoming
Lazard Capital Markets Sixth Annual Healthcare Conference on Wednesday,
November 18, 2009 at 1:15 pm ET in New York City. CryoLife's live
presentation may be accessed through its Web site, www.cryolife.com, on the
Investor Relations page. An archived copy of the presentation will be
available for 90 days on the same Web site.
CryoLife is also scheduled to present at the Sidoti & Company Emerging Growth
Institutional Investor Forum on November 20, 2009. D. Ashley Lee, executive
vice president, chief operating officer and chief financial officer will
present at 9:40 am ET in New York City.
About CryoLife
Founded in 1984, CryoLife, Inc. is a leader in the processing and distribution
of implantable living human tissues for use in cardiac and vascular surgeries
throughout the U.S. and Canada. The Company's CryoValve® SG pulmonary heart
valve, processed using CryoLife's proprietary SynerGraft® technology, has FDA
510(k) clearance for the replacement of diseased, damaged, malformed, or
malfunctioning native or prosthetic pulmonary valves. The Company's
CryoPatch® SG pulmonary cardiac patch has FDA 510(k) clearance for the repair
or reconstruction of the right ventricular outflow tract (RVOT), which is a
surgery commonly performed in children with congenital heart defects, such as
Tetralogy of Fallot, Truncus Arteriosus, and Pulmonary Atresia. CryoPatch SG
is distributed in three anatomic configurations: pulmonary hemi-artery,
pulmonary trunk, and pulmonary branch. The Company's BioGlue® Surgical
Adhesive is FDA approved as an adjunct to sutures and staples for use in adult
patients in open surgical repair of large vessels. BioGlue is also CE marked
in the European Community and approved in Canada and Australia for use in soft
tissue repair. The Company's BioFoam® Surgical Matrix is CE marked in the
European Community for use as an adjunct in the sealing of abdominal
parenchymal tissues (liver and spleen) when cessation of bleeding by ligature
or other conventional methods is ineffective or impractical. BIOGLUE
Aesthetic(TM) Medical Adhesive is CE marked in the European Community for
periosteal fixation following endoscopic browplasty (brow lift) in
reconstructive plastic surgery and is distributed by a third party for this
indication. CryoLife distributes HemoStase(TM), a hemostatic agent, in much
of the U.S. for use in cardiac and vascular surgery and in the European
Community and Canada for cardiac, vascular, and general surgery, subject to
certain exclusions.
For additional information about the Company, visit CryoLife's Web Site:
http://www.cryolife.com.
Media Contacts:
D. Ashley Lee
Executive Vice President, Chief Financial Officer and
Chief Operating Officer
Phone: 770-419-3355
SOURCE CryoLife, Inc.
D. Ashley Lee, Executive Vice President, Chief Financial Officer and Chief
Operating Officer, +1-770-419-3355
